0001144204-17-051728.txt : 20171011 0001144204-17-051728.hdr.sgml : 20171011 20171011102123 ACCESSION NUMBER: 0001144204-17-051728 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20171010 FILED AS OF DATE: 20171010 DATE AS OF CHANGE: 20171011 FILER: COMPANY DATA: COMPANY CONFORMED NAME: China Biologic Products Holdings, Inc. CENTRAL INDEX KEY: 0001369868 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 752308816 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34566 FILM NUMBER: 171131963 BUSINESS ADDRESS: STREET 1: 18TH FL, JIALONG INTERNATIONALBUILDING STREET 2: 19 CHAOYANG PARK ROAD, CHAOYANG DISTRICT CITY: BEIJING STATE: F4 ZIP: 100125 BUSINESS PHONE: 86-10-6598-3111 MAIL ADDRESS: STREET 1: 18TH FL, JIALONG INTERNATIONALBUILDING STREET 2: 19 CHAOYANG PARK ROAD, CHAOYANG DISTRICT CITY: BEIJING STATE: F4 ZIP: 100125 FORMER COMPANY: FORMER CONFORMED NAME: China Biologic Products, Inc. DATE OF NAME CHANGE: 20070213 FORMER COMPANY: FORMER CONFORMED NAME: GRC Holdings, Inc. DATE OF NAME CHANGE: 20060721 6-K 1 v476640_6k.htm 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Form 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2017

Commission File Number 001-34566

 

 

 

China Biologic Products Holdings, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

18th Floor, Jialong International Building, 19 Chaoyang Park Road

Chaoyang District, Beijing 100125

People’s Republic of China

(+86) 10-6598-3111

(Address of principal executive office)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨ 

 

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨ 

 

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.
Date: October 10, 2017   By:  /s/ David (Xiaoying) Gao
        Name: David (Xiaoying) Gao
        Title: Chief Executive Officer

 

 

 

 

 

EXHIBIT INDEX

 

Exhibit Number

Description

99.1 Press release issued by the Company dated October 9, 2017

 

 

EX-99.1 2 v476640_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

FOR RELEASE October 9, 2017

 

China Biologic Receives Approval for Commercial Manufacturing of Human Fibrinogen

 

BEIJING, China – October 9, 2017 – China Biologic Products Holdings, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that Shandong Taibang Biological Products Co., Ltd. (“Shandong Taibang”), the Company’s majority-owned subsidiary, has received approval from the China Food and Drug Administration (the “CFDA”) for commercial manufacturing of human fibrinogen (“Fibrinogen”) at its facility in Shandong Province. The Company expects that Shandong Taibang will receive the good manufacturing practice certificate issued by CFDA within a month and commence commercial production immediately thereafter, and expects the first batch of products to be released to market by the end of 2017.

 

Human fibrinogen is mainly used to treat (a) congenital fibrinogen reduction or deficiency and (b) acquired fibrinogen deficiency associated with serious liver damage, cirrhosis, disseminated intravascular coagulation or coagulation disorder resulting from the lack of fibrinogen related to postpartum hemorrhage, major surgery, trauma, or acute bleeding. China Biologic began pre-clinical research for Fibrinogen in 2008 and received approval to begin Phase III clinical trials for Fibrinogen in 2012. The CFDA completed on-site inspection of Shandong Taibang’s production facility in late 2016 and completed on-site clinical data inspection at various hospitals that carried out the phase III clinical trials during the second quarter of 2017.

 

Mr. David (Xiaoying) Gao, Chairman and Chief Executive Officer of China Biologic, commented, “We are very excited to receive this long-awaited approval from the CFDA to launch our Fibrinogen production. Fibrinogen products have been in short supply in China over the last several years with prices experiencing significant increases since the NDRC lifted price-ceiling controls in early 2015. We believe our newly launched Fibrinogen products with our applied patent manufacturing process will address under-supplied market conditions and offer premium quality treatment to congenital fibrinogen deficiency and acquired fibrinogen deficiency patients. We expect to see meaningful profit contribution from Fibrinogen in 2018 and are confident our Fibrinogen products will solidify our leadership in the China coagulation market and unlock significant market growth potential over the long term.”

 

 

 

 

About China Biologic Products Holdings, Inc.

 

China Biologic Products Holdings, Inc. (NASDAQ: CBPO) is a leading fully integrated plasma-based biopharmaceutical company in China. The Company’s products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosage forms of plasma products through its indirect majority-owned subsidiary, Shandong Taibang Biological Products Co., Ltd. and its wholly owned subsidiary, Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi’an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals, distributors and other healthcare facilities in China. For additional information, please see the Company’s website www.chinabiologic.com.

 

Safe Harbor Statement

 

This news release may contain certain “forward-looking statements” relating to the business of China Biologic Products Holdings, Inc. and its subsidiaries. All statements, other than statements of historical fact included herein, are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “intend,” “believe,” “expect,” “are expected to,” “will,” or similar expressions, and involve known and unknown risks and uncertainties. Among other things, the Company’s plans regarding the production and sale of human fibrinogen products and the management’s quotations in this news release contain forward-looking statements. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect.

 

Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including, without limitation, potential delay or failure to obtain the good manufacturing practice certificate from the CFDA, potential inability to achieve the expected production capacities, potential change in market demand for human fibrinogen and other plasma products, and potential additional regulatory restrictions on its operations and those additional risks and uncertainties discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

 

 

Contact:

 

China Biologic Products Holdings, Inc.

Mr. Ming Yin

Senior Vice President

Phone: +86-10-6598-3099

Email: ir@chinabiologic.com

 

ICR Inc.

Mr. Bill Zima

Phone: +86-10-6583-7511 or +1-646-405-5191

E-mail: bill.zima@icrinc.com

 

 

GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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end